Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium response in bipolar disorder.
BACKGROUND
Previously, we have found an association between the -48 A/G polymorphism of the dopamine receptor D1 (DRD1) gene and bipolar disorder. The aim of the present study was to investigate a possible association of this polymorphism with the quality of the prophylactic lithium response in bipolar patients.


METHODS
Ninety-two patients (39 male, 53 female), aged 30-77 (mean: 54 years) were studied. They have received lithium for prophylactic purposes for 5-27 years (mean: 15 years). Twenty-four patients were identified as excellent lithium responders (ER), 48 patients as partial responders (PR), and 20 patients were non-responders (NR). They all were genotyped for -48 A/G polymorphism of the DRD1 gene.


RESULTS
The frequency of G/G genotype in ER, PR, and NR patients was 21%, 48%, and 60%, respectively, and the frequency of G allele was 58%, 76%, and 80%, respectively.


CONCLUSIONS
The results obtained suggest that the higher frequency of G allele, and G/G genotype, which has been associated with a predisposition to bipolar illness, is also connected with a poorer prophylactic effect of lithium.
Rybakowski
J K
JK
Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland. rybakows@wlkp.top.pl
Dmitrzak-Weglarz
M
M
Suwalska
A
A
Leszczynska-Rodziewicz
A
A
Hauser
J
J
D000328:Adult; D000368:Aged; D018692:Antimanic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000235:genetics* / Q000517:prevention & control*; D004252:DNA Mutational Analysis; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D018021:Lithium Chloride / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D017447:Receptors, Dopamine D1 / Q000235:genetics*
D018692:Antimanic Agents; D017447:Receptors, Dopamine D1; D018021:Lithium Chloride